Author: Himanshu Patni
21 November 2022
Global Short bowel syndrome market is expected to register a CAGR of around 27% over the period of 2021-2027. Short bowel syndrome (SBS) is a metabolic disorder caused by dysfunction or elimination of the small intestine due to surgery for gastrointestinal disorders. The result can be malabsorption, diarrhea, steatorrhea, water and electrolyte imbalances, and malnutrition. Initial treatment for short bowel syndrome includes maintaining good nutrition, maximizing the absorption area of the remaining intestine, and avoiding complications. One of the main symptoms of short bowel syndrome is diarrhea, which causes dehydration, malnutrition, and rapid unexplained weight loss in most patients. The global short bowel syndrome market is anticipated to witness an uptick with the growing number of accident cases. For instance, according to WHO, approximately 1.3 million people die each year as a result of road traffic crashes.93% of the world’s fatalities on the roads occur in low- and middle-income countries, even though these countries have approximately 60% of the world’s vehicles. In many severe cases, the small intestine gets damaged due to which some length or part has to be removed by the doctors to not get infections. Owing to these glaring statistics the demand for short bowel syndrome is anticipated to grow in the forthcoming years.
For a detailed analysis of the Global Short Bowel Syndrome Market browse through – https://univdatos.com/report/short-bowel-syndrome-market/
Based on product type, the market is classified into glucagon-like peptide- 2 (GLP2), growth hormone, glutamine, and others. Amongst products, the GLP2 category accounted for a significant share of the market. The only GLP-2 analog available on the market for the treatment of short bowel syndrome is Gattex and Revestive. the increase in prescriptions for Gattex therapy contributes to the growth of the market.
Based on distribution channels, the market is categorized into hospital pharmacies, retail pharmacies, and online sales. Among these, the hospital pharmacies are expected to witness a considerable CAGR during the forecast period due to an increase in patients in hospital settings and rising implementation of therapy.
Request for Sample of the report browse through – https://univdatos.com/get-a-free-sample-form-php/?product_id=23498
For a better understanding of the market adoption of short bowel syndrome market, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the short bowel syndrome industry in 2020 owing to due to the revenue generated by Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S.
Some of the major players operating in the market include Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., Pharmascience, Inc., and Nestle.
Global Short Bowel Syndrome Market Segmentation
Market Insight, by Product
Market Insight, by Distribution Channel
Market Insight, by Region
Top Company Profiles
Get a call back
